Skip Navigation

European Heart Journal 1989 10(Supplement F):134-136; doi:10.1093/eurheartj/10.suppl_F.134
Copyright © 1989 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sievert, H.
Right arrow Articles by Bussmann, W.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sievert, H.
Right arrow Articles by Bussmann, W.-D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 The European Society of Cardiology

Coronary stenosis dilation by low dose intravenous nitroglycerin

H. Sievert, G. Selzer, W. Schneider, G. Kober, M. Kaltenbach and W.-D. Bussmann

Department of Cardiology, Center of Internal Medicine, University Hospital Frankfurt F.R.G.

Address for correspondence: Dr med. H. Sievert, Abteilung für Kardiologie, Zentrum der Inneren Medizin, Klinikum der Universität, Theodor-Stern-Kai 7, D-6000 Frankfurt am Main, F.R.G.

In a randomized double-blind study, 40 patients with coronary heart disease received either 0·025 mg nitroglycerin or placebo intravenously. Before and 2–3 min after injection, the aortic and left ventricular pressures were recorded and coronary angiography was performed.

Mean heart rate, systolic and diastolic aortic pressure, left ventricular filling pressure and the pre-and poststenotic coronary artery diameters, as well as the diameters of representative distal coronary artery segments showed no significant changes. Coronary artery stenosis diameters remained unchanged after placebo (1·01±0·5 to 1·13±0·49mm; n.s.) but increased significantly after nitroglycerin from 1·15±0·68 to 1·32±0·73mm (P<0·01).

Since it has been demonstrated, on the other hand, that the same dose of nitroglycerin reveals antianginal activity, it can be hypothesized from these results that dilatation of coronary stenoses plays an important role in the antianginal action of nitroglycerin. Strong haemodynamic effects do not appear to be a prerequisite of the beneficial effects of nitroglycerin.

Key Words: Nitroglycerin • coronary stenosis dilatation • low dose nitroglycerin • intravenous nitroglycerin • antianginal effects


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
J. Abrams
The Role of Nitrates in Coronary Heart Disease
Arch Intern Med, February 27, 1995; 155(4): 357 - 364.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.